RxDoctor Payments Data

Jonathan Fisher, MD

Transplant Surgery · la Jolla, CANPI 1063490670

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,962, 2.9 times the $674 reported in 2019.

$3,453in general payments, 2019–2025

Across 114 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$700
  • Gilead$348
  • Takeda Pharmaceuticals U.S.A., Inc.$200
  • Merck$195
  • Histosonics, Inc.$168
  • Ipsen Biopharmaceuticals, Inc$167
  • plus $2K from 28 others
$1,352in research payments, 2019–2025

Across 2 payments — averaging $675.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Transmedics, Inc.$1K

What the payments were for

  • Food & beverage$3,40799%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,453 in reported general payments places this provider in the 60th percentile of 56 transplant surgery providers in California.

See all transplant surgery providers in California

Medicare billing

Part B allowed, 2024
$142,816
Medicare patients
160
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Valganciclovir Hcl25$6,293
Ursodiol25$2,210
Famotidine34$351
Pantoprazole Sodium42$283
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim26$102
Amlodipine Besylate17$80
Metoprolol Tartrate15$13

Paid to pharmacies, not to this prescriber.

Other transplant surgery in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →